Q3-osavuosiraportti
14 päivää sittenTarjoustasot
First North Denmark
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q3-osavuosiraportti | 22.10. | |
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 27.2. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·19 t sittenYes, I can't make sense of this stock. It's falling, why is that? What is the reason people are dumping the stock? Now, in any case, I have bought at a discount price. As soon as the products become legal, sales will pick up. In my opinion, their guidance is very conservative.·14 t sittenIt's fine by me that the stock doesn't cost more; for my sake, it can very well stay at this level, so I can manage to buy many more shares for little money before Canabis medicin becomes eligible for reimbursement.
·20 t sitten · MuokattuTechnical analysis 19/11/25 (NFA) https://www.tradingview.com/x/nyvxGmpm/ https://www.tradingview.com/x/NmiXdBHN/ The price has hit Fibonacci Extension 1.618 (price 2.59kr - topped 2.8kr)), which was respected very nicely. This triggered a natural pullback as early investors took profit after the latest impulsive uptrend. The most important support is now found around 1.60 kr, which is a massive confluence area consisting of: • Previous top in the structure • VAH (Value Area High) • POC (Point of Control) • AVWAP from the original impulse up from the previous ascending triangle • Golden Pocket retracement • A large volume cluster from the entire range, which the price is now potentially backtesting This means that what was previously resistance can now very naturally function as strong support. Technically, this is therefore an extremely important area to hold – and an area where larger players statistically often accumulate if the overall trend is to continue upwards. Stenocare has had a period filled with significant news, which together strengthens both the case and future prospects: 🔹 Acquisition of CannGros A strategic strong move that expands Stenocare's market access, strengthens distribution channels, and increases product breadth. The acquisition is not cosmetic – it changes the real market position. At the same time, it makes no sense for CannGros to sell their Stenocare shares quickly. They have a much greater incentive to hold the shares and only sell at higher prices, which in itself is a bullish signal about future expectations. 🔹 Corrected share figures The official figures for the capital increase have been updated to: • 38,403,745 shares before • 43,403,745 shares after This provides clarity regarding market capitalization and strengthens transparency in the process. 🔹 Massive growth in Q2 and Q3 The company delivered: • 131 % growth in Q2 • Further growth in Q3 This demonstrates that Stenocare is not just surviving – they are scaling. 🔹 Forward-looking outlook Management reports both: • increasing activity • growing demand • expanded product range • stronger commercial position • momentum after the acquisition Several pieces are falling into place at the same time, both technically and fundamentally. Stenocare is currently in a sweet spot: 🔹Technical: A natural correction down into the largest support area, where several indicators converge (VAH, POC, AVWAP, Golden Pocket, volume cluster). This is typically an area where large buyers enter – if the trend is to continue. 🔹 Fundamental: The acquisition of CannGros, adjusted share figures, growth in Q2/Q3, and strategic advantages provide a strong foundation for long-term optimism. CannGros' incentive not to sell now strengthens the bull case. All in all, Stenocare is in the midst of a momentum shift, where both TA and FA point in the same direction. Remember that the price must correct for the trend to build value and remain healthy. Profit-taking is completely natural at this stage. Personally, I am long-term and have not yet taken profit. Have a good day! :-)
·1 päivä sittenI just saw the interview between cro, cfo and Helge. There is no lock-up period on the shares, but steno does not expect dancann to sell out immediately as they benefit more from the price rising. I am again only bullish about the company and the future and expect many more good days than bad.·21 t sittenI still imagine that Germany is the primary catalyst as the "patient market" alone is almost double the entire population of Denmark.·21 t sittenStenocare has put a lot of effort into several markets without really breaking through. Germany, to my knowledge, has however been good. My hope is just that canngros' revenue is in markets where Stenocare's largest revenue already lies, because that makes it easier to reap the great benefits of the acquisition. I'm not so keen on a lot of revenue spread across a lot of markets. It costs a lot of effort and money. Then I would rather have increased focus on the good markets.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
14 päivää sittenUutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·19 t sittenYes, I can't make sense of this stock. It's falling, why is that? What is the reason people are dumping the stock? Now, in any case, I have bought at a discount price. As soon as the products become legal, sales will pick up. In my opinion, their guidance is very conservative.·14 t sittenIt's fine by me that the stock doesn't cost more; for my sake, it can very well stay at this level, so I can manage to buy many more shares for little money before Canabis medicin becomes eligible for reimbursement.
- ·20 t sitten · MuokattuTechnical analysis 19/11/25 (NFA) https://www.tradingview.com/x/nyvxGmpm/ https://www.tradingview.com/x/NmiXdBHN/ The price has hit Fibonacci Extension 1.618 (price 2.59kr - topped 2.8kr)), which was respected very nicely. This triggered a natural pullback as early investors took profit after the latest impulsive uptrend. The most important support is now found around 1.60 kr, which is a massive confluence area consisting of: • Previous top in the structure • VAH (Value Area High) • POC (Point of Control) • AVWAP from the original impulse up from the previous ascending triangle • Golden Pocket retracement • A large volume cluster from the entire range, which the price is now potentially backtesting This means that what was previously resistance can now very naturally function as strong support. Technically, this is therefore an extremely important area to hold – and an area where larger players statistically often accumulate if the overall trend is to continue upwards. Stenocare has had a period filled with significant news, which together strengthens both the case and future prospects: 🔹 Acquisition of CannGros A strategic strong move that expands Stenocare's market access, strengthens distribution channels, and increases product breadth. The acquisition is not cosmetic – it changes the real market position. At the same time, it makes no sense for CannGros to sell their Stenocare shares quickly. They have a much greater incentive to hold the shares and only sell at higher prices, which in itself is a bullish signal about future expectations. 🔹 Corrected share figures The official figures for the capital increase have been updated to: • 38,403,745 shares before • 43,403,745 shares after This provides clarity regarding market capitalization and strengthens transparency in the process. 🔹 Massive growth in Q2 and Q3 The company delivered: • 131 % growth in Q2 • Further growth in Q3 This demonstrates that Stenocare is not just surviving – they are scaling. 🔹 Forward-looking outlook Management reports both: • increasing activity • growing demand • expanded product range • stronger commercial position • momentum after the acquisition Several pieces are falling into place at the same time, both technically and fundamentally. Stenocare is currently in a sweet spot: 🔹Technical: A natural correction down into the largest support area, where several indicators converge (VAH, POC, AVWAP, Golden Pocket, volume cluster). This is typically an area where large buyers enter – if the trend is to continue. 🔹 Fundamental: The acquisition of CannGros, adjusted share figures, growth in Q2/Q3, and strategic advantages provide a strong foundation for long-term optimism. CannGros' incentive not to sell now strengthens the bull case. All in all, Stenocare is in the midst of a momentum shift, where both TA and FA point in the same direction. Remember that the price must correct for the trend to build value and remain healthy. Profit-taking is completely natural at this stage. Personally, I am long-term and have not yet taken profit. Have a good day! :-)
- ·1 päivä sittenI just saw the interview between cro, cfo and Helge. There is no lock-up period on the shares, but steno does not expect dancann to sell out immediately as they benefit more from the price rising. I am again only bullish about the company and the future and expect many more good days than bad.·21 t sittenI still imagine that Germany is the primary catalyst as the "patient market" alone is almost double the entire population of Denmark.·21 t sittenStenocare has put a lot of effort into several markets without really breaking through. Germany, to my knowledge, has however been good. My hope is just that canngros' revenue is in markets where Stenocare's largest revenue already lies, because that makes it easier to reap the great benefits of the acquisition. I'm not so keen on a lot of revenue spread across a lot of markets. It costs a lot of effort and money. Then I would rather have increased focus on the good markets.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q3-osavuosiraportti | 22.10. | |
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 27.2. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
14 päivää sittenUutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q3-osavuosiraportti | 22.10. | |
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 27.2. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·19 t sittenYes, I can't make sense of this stock. It's falling, why is that? What is the reason people are dumping the stock? Now, in any case, I have bought at a discount price. As soon as the products become legal, sales will pick up. In my opinion, their guidance is very conservative.·14 t sittenIt's fine by me that the stock doesn't cost more; for my sake, it can very well stay at this level, so I can manage to buy many more shares for little money before Canabis medicin becomes eligible for reimbursement.
- ·20 t sitten · MuokattuTechnical analysis 19/11/25 (NFA) https://www.tradingview.com/x/nyvxGmpm/ https://www.tradingview.com/x/NmiXdBHN/ The price has hit Fibonacci Extension 1.618 (price 2.59kr - topped 2.8kr)), which was respected very nicely. This triggered a natural pullback as early investors took profit after the latest impulsive uptrend. The most important support is now found around 1.60 kr, which is a massive confluence area consisting of: • Previous top in the structure • VAH (Value Area High) • POC (Point of Control) • AVWAP from the original impulse up from the previous ascending triangle • Golden Pocket retracement • A large volume cluster from the entire range, which the price is now potentially backtesting This means that what was previously resistance can now very naturally function as strong support. Technically, this is therefore an extremely important area to hold – and an area where larger players statistically often accumulate if the overall trend is to continue upwards. Stenocare has had a period filled with significant news, which together strengthens both the case and future prospects: 🔹 Acquisition of CannGros A strategic strong move that expands Stenocare's market access, strengthens distribution channels, and increases product breadth. The acquisition is not cosmetic – it changes the real market position. At the same time, it makes no sense for CannGros to sell their Stenocare shares quickly. They have a much greater incentive to hold the shares and only sell at higher prices, which in itself is a bullish signal about future expectations. 🔹 Corrected share figures The official figures for the capital increase have been updated to: • 38,403,745 shares before • 43,403,745 shares after This provides clarity regarding market capitalization and strengthens transparency in the process. 🔹 Massive growth in Q2 and Q3 The company delivered: • 131 % growth in Q2 • Further growth in Q3 This demonstrates that Stenocare is not just surviving – they are scaling. 🔹 Forward-looking outlook Management reports both: • increasing activity • growing demand • expanded product range • stronger commercial position • momentum after the acquisition Several pieces are falling into place at the same time, both technically and fundamentally. Stenocare is currently in a sweet spot: 🔹Technical: A natural correction down into the largest support area, where several indicators converge (VAH, POC, AVWAP, Golden Pocket, volume cluster). This is typically an area where large buyers enter – if the trend is to continue. 🔹 Fundamental: The acquisition of CannGros, adjusted share figures, growth in Q2/Q3, and strategic advantages provide a strong foundation for long-term optimism. CannGros' incentive not to sell now strengthens the bull case. All in all, Stenocare is in the midst of a momentum shift, where both TA and FA point in the same direction. Remember that the price must correct for the trend to build value and remain healthy. Profit-taking is completely natural at this stage. Personally, I am long-term and have not yet taken profit. Have a good day! :-)
- ·1 päivä sittenI just saw the interview between cro, cfo and Helge. There is no lock-up period on the shares, but steno does not expect dancann to sell out immediately as they benefit more from the price rising. I am again only bullish about the company and the future and expect many more good days than bad.·21 t sittenI still imagine that Germany is the primary catalyst as the "patient market" alone is almost double the entire population of Denmark.·21 t sittenStenocare has put a lot of effort into several markets without really breaking through. Germany, to my knowledge, has however been good. My hope is just that canngros' revenue is in markets where Stenocare's largest revenue already lies, because that makes it easier to reap the great benefits of the acquisition. I'm not so keen on a lot of revenue spread across a lot of markets. It costs a lot of effort and money. Then I would rather have increased focus on the good markets.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt